Cannabinoids for Psychiatric Indications?: What Physicians Need to Know-View Presentation

Video Transcription

Video Summary

In the webinar on Medical Cannabis for Psychiatric Indications led by Dr. Ranjith Radhakrishnan, the speaker discussed the increasing legalization of medical cannabis in the U.S., the pharmacology of phytocannabinoids, and their impact on the endocannabinoid system. Studies on THC and CBD for psychiatric disorders were reviewed, with limited evidence for efficacy due to concerns about dosing and adverse effects. The challenges faced by clinicians, trends in cannabis usage, and ongoing research efforts were also highlighted. In the video transcript, Dr. Radhakrishnan discussed the low evidence for medical cannabis use in psychiatric conditions, emphasizing risks such as cannabis use disorder, withdrawal symptoms, cognitive deficits, and potential dependence. Monitoring dosages, routes of administration, and harm reduction strategies were deemed important, with limited evidence for treatment options for cannabis withdrawal. Dr. Radhakrishnan stressed the need for evidence-based approaches and more randomized controlled trials to better understand the role of medical cannabis in psychiatric care.

Keywords

Medical Cannabis

Psychiatric Indications

Dr. Ranjith Radhakrishnan

Legalization

Phytocannabinoids

Endocannabinoid System

THC

CBD

Efficacy

Cannabis Use Disorder

Cognitive Deficits

Withdrawal Symptoms

Randomized Controlled Trials